Pharmacokinetics of carbetocin, a long-acting oxytocin analogue, following intravenous administration in horses.

Summary

Persistent post-mating endometritis and retained fetal membranes represent significant reproductive challenges in mares, traditionally managed through ecbolic agents with variable efficacy and frequent dosing requirements. Schramme and colleagues investigated the pharmacokinetic profile and safety of carbetocin, a synthetic oxytocin analogue with prolonged activity, following intravenous administration in horses to establish whether this agent might offer advantages over conventional therapies. The researchers characterised the drug's absorption, distribution, and elimination kinetics alongside tolerance data, providing the foundational pharmacological information necessary for clinical protocol development. Understanding carbetocin's duration of action and plasma concentrations is critical for determining optimal dosing intervals and clinical efficacy in treating both post-mating endometritis and retained placental tissue. These findings have direct relevance for practitioners seeking more effective reproductive management strategies, particularly where single or fewer administrations might achieve therapeutic goals compared to repeated dosing with conventional ecbolics.

Read the full abstract on PubMed

Key Findings

• •Carbetocin is a long-acting oxytocin analogue suitable for evaluation as an ecbolic agent in mares
• •Pharmacokinetic profile and tolerability of carbetocin following intravenous administration was assessed in horses
• •Study establishes baseline data for carbetocin use in equine reproductive conditions

Conditions Studied